/
Cardiovascular
Coronary Artery Disease
55
Pipeline Programs↗
146
Active Trials↗
62
Companies Involved↗
Coronary Artery Disease is a moderately active landscape with 55 programs across 62 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., Hexun Biosciences Co., LTD., Ribocure Pharmaceuticals AB. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical38
Phase 23
Phase 313
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
43 of 48 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 95% of 55 pipeline programs.
Analysis
Trial Status
364
clinical trials
Completed148 · 41%
Recruiting77 · 21%
Unknown status51 · 14%
Not yet recruiting35 · 10%
Active, not recruiting28 · 8%
Terminated13 · 4%
Other12 · 3%
Clinical Trials
Trial Activity
364 trials
Page 1 of 25
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)